Here are five observations:
1. The scaffold has already been designated as a Humanitarian Use Device, which speeds the approval process.
2. InVivo is currently conducting a clinical study, INSPIRE, to test the device on patients with complete acute thoracic SCI.
3. InVivo plans to also conduct trials on cervical spine injuries later this year. The company wants to combine neural stem cells with a hydrogel to inject stem cell trails across SCI.
4. Based on the trials’ successes so far, InVivo is set for final approval in about two years.
5. InVivo’s stock has improved, as investors notice the company’s potential.
More articles on devices:
SpineCraft shows 4 technologies at AANS/CNS Spine Summit
Carestream introduces cone beam CT system for orthopedic practitioners — 4 insights
Anika’s CINGAL receives CE Mark approval — 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
